Literature DB >> 23685538

Impact of international normalized ratio and activated clotting time on unfractionated heparin dosing during ablation of atrial fibrillation.

Ismail Hamam1, Emile G Daoud, Jianying Zhang, Steven J Kalbfleisch, Ralph Augostini, Marshall Winner, Shane Tsai, Troy E Rhodes, Mahmoud Houmsse, Zhenguo Liu, Charles J Love, Jaret Tyler, Molly Sachdev, Raul Weiss, John D Hummel.   

Abstract

BACKGROUND: For ablation of atrial fibrillation, it is unclear how baseline international normalized ratio (INR) affects the dosing of unfractionated heparin (UFH). METHODS AND
RESULTS: A retrospective review of 170 consecutive patients undergoing atrial fibrillation ablation with baseline activated clotting time (ACT) and INR values was performed. Patients were grouped according to INR <2.0 (G<2; n=129) and INR ≥2.0 (G≥2; n=41). Clinical variables, UFH doses, and ACT values were recorded. An equation was derived to calculate the first bolus of UFH required to achieve an ACT ≥300 seconds, and this was subsequently assessed in 168 patients. For the initial 170 patients, the baseline INR (2.47±0.31 versus 1.53±0.31) and ACT (185±26 versus 153±30 seconds) were significantly greater in G≥2 (P<0.001). The amount of UFH to achieve the first ACT ≥300 seconds was significantly higher for G<2 versus G≥2 (9701±2390 versus 8268±2366 U; P=0.0001). Baseline INR, ACT, and weight were predictors of the UFH dosage to achieve an ACT ≥300 seconds. An equation derived to achieve an ACT ≥300 seconds after a single bolus of UFH met this end point in 160 of 168 patients (95%).
CONCLUSIONS: Baseline INR and ACT, in addition to weight, are the only predictors of UFH dosage needed to achieve an ACT ≥300 seconds. A derived equation predicted the UFH dosage to achieve an ACT ≥300 seconds.

Entities:  

Keywords:  anticoagulants; atrial fibrillation; catheter ablation; heparin; warfarin

Mesh:

Substances:

Year:  2013        PMID: 23685538     DOI: 10.1161/CIRCEP.113.979088

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  4 in total

1.  Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.

Authors:  Anne-Céline Martin; Sarah Lessire; Isabelle Leblanc; Anne-Sophie Dincq; Ivan Philip; Isabelle Gouin-Thibault; Anne Godier
Journal:  Clin Cardiol       Date:  2018-05-10       Impact factor: 2.882

2.  Real-life experience with a new anticoagulation regimen for patients undergoing left-sided ablation procedures.

Authors:  Charles Dussault; Santiago Rivera; Mariano Badra-Verdu; Felix Ayala-Paredes; Jean-François Roux
Journal:  Indian Pacing Electrophysiol J       Date:  2016-10-21

3.  Intra-procedural anticoagulation protocols for left-sided cardiac ablations: Striking a balance between risk and benefit.

Authors:  Konstantinos C Siontis
Journal:  Indian Pacing Electrophysiol J       Date:  2016-12-18

4.  The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation.

Authors:  Yutaro Mukai; Kyoichi Wada; Koji Miyamoto; Kazuki Nakagita; Mai Fujimoto; Kouichi Hosomi; Takeshi Kuwahara; Mitsutaka Takada; Kengo Kusano; Akira Oita
Journal:  J Arrhythm       Date:  2017-07-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.